Methicillin-resistant Staphylococcus aureus: The other emerging resistant gram-positive coccus among liver transplant recipients

Clinical Infectious Diseases

Volumn 30, Issue 2, 2000, Pages 322-327

  Singh, Nina ^a,c   Paterson, David L ^a   Chang, Feng Yee ^a,b   Gayowski, Timothy ^a   Squier, Cheryl ^a   Wagener, Marilyn M ^a   Marino, Ignazio R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; GENTAMICIN; RIFAMPICIN; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; GRAM POSITIVE BACTERIUM; HIGH RISK PATIENT; HUMAN; INFECTION RATE; INFECTION RISK; LIVER TRANSPLANTATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; STAPHYLOCOCCUS INFECTION;

ADULT; AGED; CROSS INFECTION; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; LENGTH OF STAY; LIVER TRANSPLANTATION; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; PENNSYLVANIA; REGISTRIES; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 0034012561     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313658     Document Type: Article

References (28)

1. 1. Moellring RC. A novel antimicrobial agent joins the battle against resistant bacteria. Ann Intern Med 1999; 130:155-7.
2. 2. Vincent JE, Bojaro DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. JAMA 1995; 274:639-44.
3. 3. Centers for Disease Control and Prevention. National Nosocomial Infection Surveillance System report: data summary from October 1986 April 1996. Atlanta: US Department of Health and Human Services, 1996.
4. 4. Ibelings MM, Bruining HA. Methicillin-resistant Staphylococcus aureus: acquisition and risk of death in patients in the intensive care unit. Eur J Surg 1998: 164:411-8.
5. 5. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340:493-501.
6. 6. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999; 5:9-17.
7. 7. Papanicolaou GA, Myers BR, Meyers J, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis 1996; 23:760-6.
8. 8. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996; 22:663-70.
9. 9. Newell KA, Millis JM, Arnow PM, et al. Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. Transplantation 1998;65:439-42.
10. 10. Chang FY, Singh N, Gayowski T, Wagener M, Marino IR. Staphylococcus aureus nasal colonization in patients with cirrhosis: prospective assessment of association with infections. Infect Control Hosp Epidemiol 1998; 19: 328-32.
11. 11. Chang FY, Singh N, Gayowski T, Wagener MM, Marino IR. Fever in liver transplant recipients in the 1990s: changing spectrum of etiologic agents. Clin Infect Dis 1998; 26:59-65.
12. 12. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions of nosocomial infections. Am J Infect Control 1988; 16:128-40.
13. 13. Singh N, Gayowski T, Wagener M, Yu VL. Infectious complications in liver recipients on tacrolimus: prospective analysis of 88 consecutive liver transplants. Transplantation 1994; 58:774-8.
14. 14. Chow JW, Yu VL. Staphylococcus aureus nasal carriage in hemodialysis patients: its role in infection and approaches to prophylaxis. Arch Intern Med 1989; 149:1258-62.
15. 15. Pujol M, Pena C, Pallares R, et al. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med 1996; 100:509-16.
16. 16. Muder RR, Brennen C, Wagener MM, et al. Methicillin-resistant staphylococcal colonization and infection in a long-term care facility. Ann Intern Med 1991; 114:107-12.
17. 17. Fagon JY, Maillet JM, Novara A. Hospital-acquired pneumonia: methicillin resistance and intensive care unit admission. Am J Med 1998; 104:17S-23S.
18. 18. Singh N, Falestiny M, Rogers P, et al. Pulmonary infiltrates in the intensive care unit: predictors and outcome. Chest 1998; 114:1129-36.
19. 19. Densen P, Clark RA, Nauseef WM. Granulocytic phagocytes. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1995:78-101.
20. 20. Bailey RJ, Woolf IL, Cullens H, et al. Metabolic inhibition of polymorpho-nuclear leucocytes in fulminant hepatic failure. Lancet 1976; 1:1162-3.
21. 21. Paterson DL, Singh N, Gayowski T, Marino IR. Pulmonary nodules in liver transplant recipients. Medicine 1998; 77:50-8.
22. 22. Falagas ME, Snydman DR, Griffith J, Werner BG, Boston Center for Liver Transplantation CMVIG Study Group. Exposure to cytomegalovirus from donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 1996; 23:468-74.
23. 23. Rand KH, Pollard RB, Merigan TC. Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med 1978; 298:951-3.
24. 24. Mulazimoglu L, Drenning SD, Muder RR. Vancomycin-gentamicin synergism revisited: effect of gentamicin susceptibility of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40:1534-5.
25. 25. Bayer AS, Morrison JO. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother 1984; 26:220-3.
26. 26. Zinner SH, Lagast H, Klastersky J. Antistaphylococcal activity of rifampin with other antibiotics. J Infect Dis 1981; 144:365-71.
27. 27. Tuazon CU, Lin MY, Sheagren JN. In vitro activity of rifampin alone and in combination with nafcillin and vancomycin against pathogenic strains of Staphylococcus aureus. Antimicrob Agents Chemother 1978; 13:759-61.
28. 28. Van Der Auwera P, Klastersky J. In vitro study of the combination of rifampin with oxacillin against Staphylococcus aureus. Rev Infect Dis 1983; 5:S509-14.